According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:
A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.
Sign up to learn about new research and developments from BioMark
Biomarkers have many potential applications in oncology including:
9
Oct, 2020
A rapid COVID-19 saliva test could be used wherever crowds gatherMaria Rantanen / Richmond News A Richmond biomedical company is in a race to create a rapid, cheap and portable saliva test for COVID-19 to help open up the economy…
READ MORE
31
Mar, 2020
An amazing show of public support for UBC disease researcher Dr. Horciao Bach, who has started his COVID-19 antibody development project. Dr. Horacio Bach is one of BioMark’s scientific advisors and is expert on antibody engineering. He has received a major grant from CIHR for COVID- 19 antibody development. More information can be found at @DiseasesUbc
READ MORESeptember 23, 2020
Vancouver, British Columbia – (September 23rd, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that on September 29, its strategic scientific advisor Dr. Donald Miller is to present on BioMark’s SSAT amantadine assay for the early detection of cancer at the prestigious Delaware Valley Drug Metabolism Discussion Group (DVDMDG). Rashid Ahmed, President and CEO of BioMark, says, “We are pleased to have Dr. Donald Miller present his important work on the SSAT amantadine assay for the early detection of cancer in […]
BioMark has been over the years, funded by various government agencies and Foundation including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta. Now BioMark is collaborating with Bio banks across Canada and United States to expand our metabolomics study.